Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07043894

Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients

A Prospective, Multicenter Study on the Efficacy and Safety of Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia (CIT) in Children, Adolescents, and Young Adults (CAYA) With Hematological and Solid Tumors

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Adolescent Chemotherapy Induced Thrombocytopenia Children Hematological Tumor Solid Tumors

Interventions Romiplostim N01

Updated 1 time since 2025 Last updated: Jun 21, 2025 Started: Jul 1, 2025 Primary completion: Sep 1, 2026 Completion: Sep 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07043894, this PHASE2 trial focuses on Adolescent and Chemotherapy Induced Thrombocytopenia and remains actively recruiting participants. Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China